As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > REGULATORY
REGULATORY
- Nobelpharma’s Tympanic Membrane Perforation Drug Clears MHLW Panel, September OK Likely
August 2, 2019
- MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
- Japan OKs FY2020 Budget Guidelines, Sets 530 Billion Yen Request Ceiling for Social Security Cost Rise
August 1, 2019
- Indonesia to Shorten Review Period for Japan-Approved Drugs
July 29, 2019
- Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
- Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
- Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
- Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
- Don’t Cause Confusion in Drug Distribution in Tax-Linked Drug Re-Pricing: JPWA
July 25, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
- Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
- Nobelpharma’s Tympanic Membrane Perforation Treatment Up for MHLW Panel Review on Aug. 1
July 23, 2019
- LDP’s Eto Secures Upper House Seat
July 22, 2019
- PMDA Reviewing Risks for Xeljanz and More
July 22, 2019
- Label Revisions Ordered for Opdivo, Keytruda, Ibrance and More
July 10, 2019
- LDP Lawmaker Seiichi Eto Launches Campaign for Upper House Election
July 5, 2019
- No Discussion in Progress for Health Coverage of Risk Reducing Mastectomies for Breast Cancer: Health Minister
July 4, 2019
- Hayashi of Japan Pension Service Tapped for Economic Affairs Division Director: MHLW Personnel Shakeup
July 3, 2019
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…